Background: Human T-cell lymphotropic virus type 1 (HTLV-I) causes not only adult T-cell leukemia (ATL) but also HTLV-I associated T-cell bronchioloalveolitis, which is often chronic and subclinical. We have experienced eight HTVL-I carriers with bronchioloalveolar carcinoma, which is known to arise from bronchioloalveolar pneumocytes. This case-control study clarified the risk of bronchioloalveolar carcinoma in HTLV-I carriers. 
Introduction
Human T-cell lymphotropic virus type 1 (HTLV-I) is a human retrovirus known to cause adult T-cell leukemia (ATL). 1, 2) This viral infection is endemic in Caribbean countries, South America, Africa, and southwestern Japan. 3, 4) The incidence of HTLC-I carriers is known to be dependent on geographic location, and as such, it is reportedly as high as 16% in the southern islands of Japan. 5) This virus has been reported to be associated with several non-malignant disorders, such as HTLV-I associated myelopathy (HAM), 6) HTLV-I associated uveitis (HAU), 7) and HTLV-I associated bronchioloalveolitis (HAB). [8] [9] [10] [11] Actually, HAB is a chronic T-cell bronchioloalveolitis, which shows an interstitial pneumonia-like shadow on chest X-p, an increased total cell count, and an increased proportion of T-cells in bronchoalveolar lavage (BAL) fluid, despite normal chest X-ray findings and pulmonary functions of the patient. 8, 9) Although HAB is often observed in patients with HTLV-I associated myelopathy (HAM), it is also observed in asymptomatic HTLV-I carriers. 12) However, no reports have described whether HTLV-I might cause lung cancer.
During the past 4 years, we diagnosed bronchioloalveolar carcinoma (BAC) in 8 patients who were carriers of HTVL-I. Actually, BAC is distinct from other lung cancers: it is usually a carcinoma in situ, characterized by tumor cell growth along alveolar septa without stromal, vascular, or pleural invasion. 13) Although most lung cancers originate from the bronchial epithelium, BAC has been considered to arise from bronchioloalveolar pneumocytes. 14) We hypothesize that chronic and subclinical HAB in HTLV-I carriers promote tumorigenesis of bronchioloalveolar pneumocytes, thereby causing BAC. Using a case-controlled study, we evaluated the risk of BAC in HTLV-1 carriers.
Materials and Methods

Eligibility
The study protocol, designed to examine serum anti-HTLV-I antibody in patients with lung cancer who had undergone surgical resection in Kumamoto University Hospital, was approved by the Ethics Committee of Kumamoto University School of Medicine.
Examination of serum anti-HTLV-I antibody
The titers of serum anti-HTLV-I antibody were examined using particle agglutination (PA) kits (Serodia; Fujirebio Inc., Tokyo, Japan). For this study, PA positivity was defined as agglutination at ≥16-fold serum dilution.
15)
Study subjects
During April 2005 -March 2008, 381 patients with primary lung cancer underwent surgical treatment at Kumamoto University Hospital. Of these, 212 patients were examined for serum anti-HTLV-I antibody. Of the 212 patients, 8 (4%) were HTLV-I positive (Table 1) ; the other 204 were negative. For the case-control study, 24 HTLV-I negative patients (1:3 case-control ratio) matched for sex, age (±3 yr), and smoking status served as controls. For each HTLV-I positive case, 3 HTLV-I negative controls were selected from 204 HTLV-I negative patients who had undergone surgical treatment on the dates nearest to those of the 8 HTLV-I positive patients. The distributions of histological type of lung cancer were compared between the case group (HTLV-I positive) and control group (HTLV-I negative). The family histories of lung cancer in first-degree and second-degree relatives were also compared between the two groups. The histological diagnosis of lung cancer was classified according to the World Health Organization (WHO) system. 13, 14) Adenocarcinoma was further subclassified into adenocarcinoma with and without a BAC component. The histological sections were reviewed by a pathologist (K.I.) who had 35 years of experience in pathological diagnosis and who was unaware of the clinical data of the patients.
Statistical analysis
All data were analyzed using Fisher's exact test. Differences between the cases and controls with p values less than 0.05 were regarded as significant. Table 2 shows characteristics of the 8 HTLV-I carriers and 24 HTLV-I negative controls. The HTLV-I carriers included 4 males and 4 females, of whom 5 had never smoked, and 3 were current smokers. The mean age of both groups was 67 ± 7 yr. Their histological types were BAC in 6 patients and adenocarcinoma with a BAC component in 2. Of them, 4 patients had a family history of lung cancer among first-degree and second-degree relatives. None of the 8 HTLV-I carriers showed abnormal lesions on chest CT, other than lung cancers. On the other hand, the histological types of the 24 control patients were BAC in 6, adenocarcinoma with a BAC component in 7, adenocarcinoma in 10, and squamous cell carcinoma in 2. The family history of lung cancer was positive in 7 of the 24 controls (29%). Table 3 presents distributions of BAC in HTLV-I positive and negative patients. Of the 8 HTLV-I positive patients, 6 (75%) had BAC, of which the frequency was significantly higher than the 6 of 24 (25%) HTLV-I negative patients (p = 0.02). 
Results
Discussion
While it has been reported that a βretrovirus-Jaagsiekte sheep retrovir us-causes pulmona r y adenocarcinoma in sheep, which resembles human BAC, 16) none of the virus has been reported to cause human lung cancer. Our case-control study showed a significantly high risk of BAC in HTLV-I carriers. Compared with other lung cancers, BAC is a distinct entity, especially in terms of tumorigenesis: BAC arises from bronchioloalveolar pneumocytes, whereas, most other lung cancers are derived from bronchial epithelium. Our data show that bronchioloalveolar pneumocytes in HTLV-I carriers are more likely to develop BAC than the pneumocytes in non-carriers are.
The age of BAC patients among HTLV-1 carriers was 67 ± 7 yr, which was the general age of lung cancer patients, casting doubt on whether or not HTLV-I is an actual cause of BAC. However, the mean age of ATL, which is caused directly by HTLV-I, was reported as about 60 years old because most HTLV-I infections are chronic. Therefore, if we assume that HTLV-I is causing BAC, it stands to reason that the mean age of HTLV-I carriers with BAC is about 60 years of age.
Although clinical or subclinical HAB is reportedly often observed in patients with HAM, 9-11) subsequent reports have described that HAB is also observed in asymptomatic HTLV-I carriers. Tumorigenesis in lung cancers is known to result from nuclear injury, including DNA translocation, activation of proto-oncogenes, or inactivation of tumor suppressor genes. Reportedly, BAC develops in transgenic mice overexpressing c-myc and epidermal growth factor (EGF). 13) Results of the present study suggest that chronic and subclinical HAB in HTVL-I carriers could cause these genetic alterations in bronchioloalveolar pneumocytes, thereby resulting in BAC.
A weakness of this study is the lack the incidence of lung cancer or BAC in a large population of HTLV-I carriers. Although no reports have described the incidence of lung cancer in HTLV-I carriers, we consider it difficult to demonstrate a higher incidence of BAC in HTLV-I carriers than in HTLV-I non-carriers for the following reasons. (1) Although HTLV-I directly causes ATL, even the ATL incidence in HTLV-I carriers is reportedly only between 1 and 5%. (2) While HTLV-1 might be exhibiting its effect on BAC indirectly through inflammatory and/or immunologic responses involving bronchioloalveolar pneumocytes, it is difficult to demonstrate a significantly higher incidence of BAC in HTLV-1 carriers than in non-carriers, even in a large population, because of its little incidence.
The next step is to demonstrate inflammatory conditions fundamentally in lung tissues of HTLV-I carriers with BAC. 
